Krisulin's DDS platform doth combine a multitude of technologies, conceived to enhance the oral absorption and bioavailability of endogenous peptides in a stable fashion. Verily, this stands as the very first such innovation in the annals of science and commerce.
Historically, the high dosage requirements for oral analog peptides have rendered their scaling a difficult affair, thereby favouring the development of small-molecule alternatives for the reduction of corpulence. Moreover, the nascent data from even the newest platforms (presently bearing INN nomenclature) doth suggest a reduced efficacy and a more frequent onset of untoward effects when set beside peptides.
Neither other existing platforms, which were designed to surmount these selfsame challenges, have yet enabled the effective oral administration of analog peptides at doses potentially significantly lower than those of other oral peptides currently in development.
